🔗 Visit the ClinicalTrials.gov page for NCT00928135
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | The osmolyte xylitol reduces the salt concentration of airway surface liquid and may enhance bacterial killing. | Proc Natl Acad Sci U S A | 2000 | 1.00 |
| 2 | State of progress in treating cystic fibrosis respiratory disease. | BMC Med | 2012 | 0.96 |
| 3 | Safety assessment of inhaled xylitol in mice and healthy volunteers. | Respir Res | 2004 | 0.86 |
| 4 | Xylitol enhances bacterial killing in the rabbit maxillary sinus. | Laryngoscope | 2004 | 0.79 |
| 5 | Bronchoscopic assessment of airway retention time of aerosolized xylitol. | Respir Res | 2006 | 0.77 |
| 6 | Safety assessment of inhaled xylitol in subjects with cystic fibrosis. | J Cyst Fibros | 2006 | 0.75 |